Basic characteristics of adult and paediatric patients with completed patient diaries and adrenal crisis.
| Characteristics . | Adult patients . | Paediatric patients . |
|---|---|---|
| Total number (n (%)) | 145 (100) | 29 (100) |
| Median age (range) in years | 32.0 (16.0-68.0) | 12.1 (0.7-18.9) |
| Sex (n (%)) | ||
| Female | 85 (58.6) | 15 (51.7) |
| Male | 60 (41.4) | 14 (48.3) |
| Phenotype (n (%)) | ||
| SW | 88 (60.7) | 23 (79.3) |
| SV | 49 (33.8) | 6 (20.7) |
| NC | 8 (5.5) | 0 (0) |
| First glucocorticoid preparation (n (%) Subgroups (n) | ||
| Hydrocortisone | 65 (44.8) 45 SW; 17 SV; 3 NC | 27 (93.1) 21 SW; 6 SV |
| Plenadren® | 7 (4.8) 4 SW; 2 SV; 1 NC | 1 (3.4) 1 SW |
| Efmody® | 13 (9.0) 5 SW; 8 SV | |
| Prednison | 9 (6.2) 5 SW; 4 SV | |
| Prednisolon | 42 (29.0) 21 SW; 17 SV; 4 NC | 1 (3.4) 1 SW |
| Dexamethason | 9 (6.2) 8 SW; 1 SV | |
| Second glucocorticoid preparation (n (%)) Subgroups (n) | ||
| None | 133 (91.7) 79 SW; 47 SV; 7 NC | 29 (100) |
| Hydrocortisone | 1 (0.7) 1 SW | |
| Prednisolone | 8 (5.5) 6 SW; 2 SV | |
| Dexamethasone | 3 (2.1) 2 SW; 1 NC | |
| HDE in mg/day (Md (IQR)) | 30.1 (13.8) | 22.5 (17.5) |
| SW | 30.0 (10.0) | 22.5 (15.0) |
| SV | 30.0 (15.0) | 26.3 (23.5) |
| NC | 15.0 (8.8) | |
| Mineralocorticoid medication | ||
| Yes | 90 (62.1) | 23 (79.3) |
| No | 55 (37.9) | 6 (20.7) |
| Mineralocorticoid in mg/day (Md (IQR)) | 0.05 (0.10) | 0.07 (0.06) |
| Total number of AC | 31 in 370.6 py | 3 in 58.6 py |
| 8.4 in 100 py | 5.1 in 100 py |
| Characteristics . | Adult patients . | Paediatric patients . |
|---|---|---|
| Total number (n (%)) | 145 (100) | 29 (100) |
| Median age (range) in years | 32.0 (16.0-68.0) | 12.1 (0.7-18.9) |
| Sex (n (%)) | ||
| Female | 85 (58.6) | 15 (51.7) |
| Male | 60 (41.4) | 14 (48.3) |
| Phenotype (n (%)) | ||
| SW | 88 (60.7) | 23 (79.3) |
| SV | 49 (33.8) | 6 (20.7) |
| NC | 8 (5.5) | 0 (0) |
| First glucocorticoid preparation (n (%) Subgroups (n) | ||
| Hydrocortisone | 65 (44.8) 45 SW; 17 SV; 3 NC | 27 (93.1) 21 SW; 6 SV |
| Plenadren® | 7 (4.8) 4 SW; 2 SV; 1 NC | 1 (3.4) 1 SW |
| Efmody® | 13 (9.0) 5 SW; 8 SV | |
| Prednison | 9 (6.2) 5 SW; 4 SV | |
| Prednisolon | 42 (29.0) 21 SW; 17 SV; 4 NC | 1 (3.4) 1 SW |
| Dexamethason | 9 (6.2) 8 SW; 1 SV | |
| Second glucocorticoid preparation (n (%)) Subgroups (n) | ||
| None | 133 (91.7) 79 SW; 47 SV; 7 NC | 29 (100) |
| Hydrocortisone | 1 (0.7) 1 SW | |
| Prednisolone | 8 (5.5) 6 SW; 2 SV | |
| Dexamethasone | 3 (2.1) 2 SW; 1 NC | |
| HDE in mg/day (Md (IQR)) | 30.1 (13.8) | 22.5 (17.5) |
| SW | 30.0 (10.0) | 22.5 (15.0) |
| SV | 30.0 (15.0) | 26.3 (23.5) |
| NC | 15.0 (8.8) | |
| Mineralocorticoid medication | ||
| Yes | 90 (62.1) | 23 (79.3) |
| No | 55 (37.9) | 6 (20.7) |
| Mineralocorticoid in mg/day (Md (IQR)) | 0.05 (0.10) | 0.07 (0.06) |
| Total number of AC | 31 in 370.6 py | 3 in 58.6 py |
| 8.4 in 100 py | 5.1 in 100 py |
Abbreviations: AC, adrenal crisis; HDE, hydrocortisone dose equivalent; NC, non-classic; py, patient years; SV, simple virilizing; SW, salt wasting.
Basic characteristics of adult and paediatric patients with completed patient diaries and adrenal crisis.
| Characteristics . | Adult patients . | Paediatric patients . |
|---|---|---|
| Total number (n (%)) | 145 (100) | 29 (100) |
| Median age (range) in years | 32.0 (16.0-68.0) | 12.1 (0.7-18.9) |
| Sex (n (%)) | ||
| Female | 85 (58.6) | 15 (51.7) |
| Male | 60 (41.4) | 14 (48.3) |
| Phenotype (n (%)) | ||
| SW | 88 (60.7) | 23 (79.3) |
| SV | 49 (33.8) | 6 (20.7) |
| NC | 8 (5.5) | 0 (0) |
| First glucocorticoid preparation (n (%) Subgroups (n) | ||
| Hydrocortisone | 65 (44.8) 45 SW; 17 SV; 3 NC | 27 (93.1) 21 SW; 6 SV |
| Plenadren® | 7 (4.8) 4 SW; 2 SV; 1 NC | 1 (3.4) 1 SW |
| Efmody® | 13 (9.0) 5 SW; 8 SV | |
| Prednison | 9 (6.2) 5 SW; 4 SV | |
| Prednisolon | 42 (29.0) 21 SW; 17 SV; 4 NC | 1 (3.4) 1 SW |
| Dexamethason | 9 (6.2) 8 SW; 1 SV | |
| Second glucocorticoid preparation (n (%)) Subgroups (n) | ||
| None | 133 (91.7) 79 SW; 47 SV; 7 NC | 29 (100) |
| Hydrocortisone | 1 (0.7) 1 SW | |
| Prednisolone | 8 (5.5) 6 SW; 2 SV | |
| Dexamethasone | 3 (2.1) 2 SW; 1 NC | |
| HDE in mg/day (Md (IQR)) | 30.1 (13.8) | 22.5 (17.5) |
| SW | 30.0 (10.0) | 22.5 (15.0) |
| SV | 30.0 (15.0) | 26.3 (23.5) |
| NC | 15.0 (8.8) | |
| Mineralocorticoid medication | ||
| Yes | 90 (62.1) | 23 (79.3) |
| No | 55 (37.9) | 6 (20.7) |
| Mineralocorticoid in mg/day (Md (IQR)) | 0.05 (0.10) | 0.07 (0.06) |
| Total number of AC | 31 in 370.6 py | 3 in 58.6 py |
| 8.4 in 100 py | 5.1 in 100 py |
| Characteristics . | Adult patients . | Paediatric patients . |
|---|---|---|
| Total number (n (%)) | 145 (100) | 29 (100) |
| Median age (range) in years | 32.0 (16.0-68.0) | 12.1 (0.7-18.9) |
| Sex (n (%)) | ||
| Female | 85 (58.6) | 15 (51.7) |
| Male | 60 (41.4) | 14 (48.3) |
| Phenotype (n (%)) | ||
| SW | 88 (60.7) | 23 (79.3) |
| SV | 49 (33.8) | 6 (20.7) |
| NC | 8 (5.5) | 0 (0) |
| First glucocorticoid preparation (n (%) Subgroups (n) | ||
| Hydrocortisone | 65 (44.8) 45 SW; 17 SV; 3 NC | 27 (93.1) 21 SW; 6 SV |
| Plenadren® | 7 (4.8) 4 SW; 2 SV; 1 NC | 1 (3.4) 1 SW |
| Efmody® | 13 (9.0) 5 SW; 8 SV | |
| Prednison | 9 (6.2) 5 SW; 4 SV | |
| Prednisolon | 42 (29.0) 21 SW; 17 SV; 4 NC | 1 (3.4) 1 SW |
| Dexamethason | 9 (6.2) 8 SW; 1 SV | |
| Second glucocorticoid preparation (n (%)) Subgroups (n) | ||
| None | 133 (91.7) 79 SW; 47 SV; 7 NC | 29 (100) |
| Hydrocortisone | 1 (0.7) 1 SW | |
| Prednisolone | 8 (5.5) 6 SW; 2 SV | |
| Dexamethasone | 3 (2.1) 2 SW; 1 NC | |
| HDE in mg/day (Md (IQR)) | 30.1 (13.8) | 22.5 (17.5) |
| SW | 30.0 (10.0) | 22.5 (15.0) |
| SV | 30.0 (15.0) | 26.3 (23.5) |
| NC | 15.0 (8.8) | |
| Mineralocorticoid medication | ||
| Yes | 90 (62.1) | 23 (79.3) |
| No | 55 (37.9) | 6 (20.7) |
| Mineralocorticoid in mg/day (Md (IQR)) | 0.05 (0.10) | 0.07 (0.06) |
| Total number of AC | 31 in 370.6 py | 3 in 58.6 py |
| 8.4 in 100 py | 5.1 in 100 py |
Abbreviations: AC, adrenal crisis; HDE, hydrocortisone dose equivalent; NC, non-classic; py, patient years; SV, simple virilizing; SW, salt wasting.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
